Bayer: Encouraging business performance across all divisions – agreements signed to divest Currenta and Animal Health

Group sales increase by 5.4 percent (Fx& portfolio adj.) to 9.830 billion euros / EBITDA before special items advances by 7.5 percent to 2.291 billion euros / Crop Science reports higher sales and substantial earnings growth / Pharmaceuticals increases sales – earnings decline due to one-time income in prior year / Consumer Health posts growth in sales (Fx& portfolio adj.) and earnings / Net income declines by 63.9 percent to 1.036 billion euros – substantial divestment gain included in prior year / Core earnings per share up by 6.4 percent to 1.16 euros / Group outlook confirmed and aligned to continuing operations
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news